Drugs / LJEVac
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01567865 Comparator | May → Dec 2012 | Japanese encephalitis | PATH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LJEVac | “Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China” NCT01567865 ↗ |
| Known as | SA 14-14-2 | “Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China” NCT01567865 ↗ |
| Modality | Vaccine | “Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine” NCT01567865 ↗ |